Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Sell
36
AUTL Quote, Financials, Valuation and Earnings
Last price:
$1.94
Seasonality move
:
13.12%
Day range:
$1.74 - $1.85
52-week range:
$1.68 - $6.63
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.00x
Volume:
557.3K
Avg. volume:
1.3M
1-year change:
-71.15%
Market cap:
$476.4M
Revenue:
$1.7M
EPS (TTM):
-$1.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
$3M | -$0.24 | -61.82% | -46.14% | $10.62 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$8.4M | -$0.15 | 4199.24% | -9.44% | $2.30 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$0.01 | 1109.31% | -69.36% | $7.89 |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
|
VRNA
Verona Pharma PLC
|
$33.5M | -$0.15 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
$1.79 | $10.62 | $476.4M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.46 | $2.30 | $116.5M | -- | $0.00 | 0% | 0.64x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$2.02 | $17.97 | $1.3M | -- | $0.00 | 0% | 1.82x |
|
MREO
Mereo BioPharma Group PLC
|
$2.53 | $7.89 | $392.5M | -- | $0.00 | 0% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
$1.63 | -- | $836.2K | -- | $0.25 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$63.55 | $81.00 | $5.4B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.987 | -- | 17.97x |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 2.439 | 20.51% | 3.54x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.756 | -- | 1.20x |
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.564 | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -1.548 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | -0.759 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$9.1M | -- | -- | -- | -$7.5M |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Autolus Therapeutics PLC vs. Competitors
-
Which has Higher Returns AUTL or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -522.15% compared to Autolus Therapeutics PLC's net margin of -43.07%. Autolus Therapeutics PLC's return on equity of -80.74% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-- -$0.31 $582M ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About AUTL or ADAP?
Autolus Therapeutics PLC has a consensus price target of $10.62, signalling upside risk potential of 493.42%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $2.30 which suggests that it could grow by 405.38%. Given that Autolus Therapeutics PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Autolus Therapeutics PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC8 0 0 ADAPAdaptimmune Therapeutics PLC3 2 0 -
Is AUTL or ADAP More Risky?
Autolus Therapeutics PLC has a beta of 2.067, which suggesting that the stock is 106.723% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.520, suggesting its more volatile than the S&P 500 by 152.023%.
-
Which is a Better Dividend Stock AUTL or ADAP?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or ADAP?
Autolus Therapeutics PLC quarterly revenues are $10.1M, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Autolus Therapeutics PLC's net income of -$82.1M is lower than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus 0.64x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M ADAPAdaptimmune Therapeutics PLC0.64x -- $40.9M -$17.6M
-
Which has Higher Returns AUTL or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -522.15% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -80.74% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-- -$0.31 $582M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About AUTL or BDRX?
Autolus Therapeutics PLC has a consensus price target of $10.62, signalling upside risk potential of 493.42%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 797.85%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC8 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is AUTL or BDRX More Risky?
Autolus Therapeutics PLC has a beta of 2.067, which suggesting that the stock is 106.723% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.
-
Which is a Better Dividend Stock AUTL or BDRX?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or BDRX?
Autolus Therapeutics PLC quarterly revenues are $10.1M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Autolus Therapeutics PLC's net income of -$82.1M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus 1.82x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M BDRXBiodexa Pharmaceuticals PLC1.82x -- -- --
-
Which has Higher Returns AUTL or MREO?
Mereo BioPharma Group PLC has a net margin of -522.15% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -80.74% beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-- -$0.31 $582M MREOMereo BioPharma Group PLC-- -$0.10 -- -
What do Analysts Say About AUTL or MREO?
Autolus Therapeutics PLC has a consensus price target of $10.62, signalling upside risk potential of 493.42%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.89 which suggests that it could grow by 210.43%. Given that Autolus Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Autolus Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC8 0 0 MREOMereo BioPharma Group PLC6 0 0 -
Is AUTL or MREO More Risky?
Autolus Therapeutics PLC has a beta of 2.067, which suggesting that the stock is 106.723% more volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.723%.
-
Which is a Better Dividend Stock AUTL or MREO?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or MREO?
Autolus Therapeutics PLC quarterly revenues are $10.1M, which are larger than Mereo BioPharma Group PLC quarterly revenues of --. Autolus Therapeutics PLC's net income of -$82.1M is lower than Mereo BioPharma Group PLC's net income of -$15M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M MREOMereo BioPharma Group PLC-- -- -- -$15M
-
Which has Higher Returns AUTL or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -522.15% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -80.74% beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-- -$0.31 $582M TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About AUTL or TCBP?
Autolus Therapeutics PLC has a consensus price target of $10.62, signalling upside risk potential of 493.42%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 2844.79%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC8 0 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is AUTL or TCBP More Risky?
Autolus Therapeutics PLC has a beta of 2.067, which suggesting that the stock is 106.723% more volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AUTL or TCBP?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or TCBP?
Autolus Therapeutics PLC quarterly revenues are $10.1M, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. Autolus Therapeutics PLC's net income of -$82.1M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
-
Which has Higher Returns AUTL or VRNA?
Verona Pharma PLC has a net margin of -522.15% compared to Autolus Therapeutics PLC's net margin of -92.29%. Autolus Therapeutics PLC's return on equity of -80.74% beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-- -$0.31 $582M VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About AUTL or VRNA?
Autolus Therapeutics PLC has a consensus price target of $10.62, signalling upside risk potential of 493.42%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 27.46%. Given that Autolus Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Autolus Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC8 0 0 VRNAVerona Pharma PLC5 0 0 -
Is AUTL or VRNA More Risky?
Autolus Therapeutics PLC has a beta of 2.067, which suggesting that the stock is 106.723% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.803%.
-
Which is a Better Dividend Stock AUTL or VRNA?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or VRNA?
Autolus Therapeutics PLC quarterly revenues are $10.1M, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Autolus Therapeutics PLC's net income of -$82.1M is lower than Verona Pharma PLC's net income of -$33.8M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Pepsi Vs Coke Stock: Which Is Best?
Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…
Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
52
RGC alert for Mar 19
Regencell Bioscience Holdings [RGC] is down 0.66% over the past day.
Sell
49
SRPT alert for Mar 19
Sarepta Therapeutics [SRPT] is up 8.72% over the past day.
Sell
46
CVNA alert for Mar 19
Carvana [CVNA] is up 5.74% over the past day.
